key: cord-0853919-dm38cr2s
authors: Singh, Jalen; Pandit, Pranav; McArthur, Andrew G.; Banerjee, Arinjay; Mossman, Karen
title: Evolutionary trajectory of SARS-CoV-2 and emerging variants
date: 2021-08-13
journal: Virol J
DOI: 10.1186/s12985-021-01633-w
sha: 4e00d084c8ebd27af823d90fb576527f7c78d847
doc_id: 853919
cord_uid: dm38cr2s

The emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more recently, the independent evolution of multiple SARS-CoV-2 variants has generated renewed interest in virus evolution and cross-species transmission. While all known human coronaviruses (HCoVs) are speculated to have originated in animals, very little is known about their evolutionary history and factors that enable some CoVs to co-exist with humans as low pathogenic and endemic infections (HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1), while others, such as SARS-CoV, MERS-CoV and SARS-CoV-2 have evolved to cause severe disease. In this review, we highlight the origins of all known HCoVs and map positively selected for mutations within HCoV proteins to discuss the evolutionary trajectory of SARS-CoV-2. Furthermore, we discuss emerging mutations within SARS-CoV-2 and variants of concern (VOC), along with highlighting the demonstrated or speculated impact of these mutations on virus transmission, pathogenicity, and neutralization by natural or vaccine-mediated immunity.

Coronaviruses (CoVs) can infect humans and animals to cause mild to severe disease, including death [1] . CoVs are divided into four genera: alpha-and beta-CoVs predominantly originate in bats and infect other mammals, while gamma-and delta-CoVs originate in and largely infect avian species [2] . CoV infection in animals is generally associated with gastric symptoms [3] , such as acute diarrhea in young pigs that are infected with porcine epidemic diarrhea virus (PEDV) and swine acute diarrhea syndrome coronavirus (SADS-CoV) [4, 5] . While CoVs mainly circulate in animals, such as pigs, camels, cats, and bats [6] , there have been at least seven documented instances where these viruses have spilled over into humans [7] . These events have led to the emergence of human coronaviruses (HCoVs) that are low and high pathogenic. The origin of the most recently emerged human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is speculated to be associated with Rhinolophus bats, but the zoonotic transmission pathway remains unknown.

HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 represent endemic and low pathogenic HCoVs, and are responsible for one-third of common cold symptoms [8] . High pathogenic HCoVs such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 cause or have caused severe disease in humans with case-fatality rates of 10.9%, 34.3%, and 2.1%, respectively [9] [10] [11] . SARS-CoV, MERS-CoV and SARS-CoV-2 are beta-CoVs [12, 13] . MERS-CoV belongs to the Merbecovirus subgenus, while SARS-CoV and SARS-CoV-2 belong to the SARS-related coronavirus (SARSr-CoV) species within the Sarbecovirus subgenus [14] . It remains unclear why most HCoVs evolved to largely cause minor illness while MERS-CoV continues to cause severe disease [15] [16] [17] . In this review, we have highlighted the origins of HCoVs and mapped positively selected for mutations within HCoV proteins to discuss the evolutionary trajectory of SARS-CoV-2. We have also discussed emerging mutations within SARS-CoV-2 and variants of concern (VOC), along with highlighting the demonstrated or speculated impact of these mutations on virus transmission, pathogenicity, and neutralization by natural or vaccine-mediated immunity.

All known HCoVs are speculated to have an evolutionary origin in bats or rodents [1, 3, 18] (Fig. 1) , with five of seven HCoVs originating in bats [3, [19] [20] [21] (Table 1) . Bats are speculated to be primordial hosts for all CoV lineages due to ubiquitous detection of diverse CoVs and constant CoV population growth, which contrasts epidemic-like growths observed in other animals [22] . Although bats and alpacas can serve as MERS-CoV reservoirs [23, 24] , dromedary camels are the major reservoir host and primary contributor to human infections [25] [26] [27] [28] (Fig. 1) . The full extent of wildlife or intermediate animal reservoirs of SARS-CoV-2 is currently unknown.

SARS-CoV-2 is believed to have originated in a seafood market in Wuhan, Hubei Province, China [29] , although limited contact-tracing at the beginning of the pandemic does not allow for definitive characterization of the exact events that led to the first human-to-human transmission, including the index patient or initial animal contact. Nonetheless, it is speculated that the natural reservoirs of SARS-CoV-2 are Rhinolophus bats (Table 1 ) since diverse SARSr-CoVs have been detected in multiple Rhinolophus species [22, 30, 31] , including RaTG13 in R. affinis [32] . RaTG13 is 96.2% identical to SARS-CoV-2 at the whole genome level [32] . Moreover, SARS-CoV-2 contains a polybasic furin-like cleavage site between S1 and S2 spike (S) protein subunits, similar to Rhinolophus CoV Fig. 1 Speculated animal origins of known human coronaviruses. HCoV species are organized chronologically (top to bottom) by their speculated dates of spill over into humans. Intermediate hosts (top to bottom) shown are alpacas, cattle, civet cats, dromedary camels, pangolins, and unknown (denoted as a question mark). Genome similarity to humans (A) indicates percentage similarity of CoV genomes detected in reservoir species with corresponding human CoV. Genome similarity to humans (B) indicates percentage similarity of CoV genomes detected in intermediate species with corresponding human CoV. Non-human CoVs that are highly pathogenic in animals, such as PEDV and SADS-CoV, are not shown here. Genomic percentage similarities were extracted from existing primary studies [20, 21, 32, 56, 60, [277] [278] [279] [280] [281] [282] [283] . Indeed, if SARS-CoV-2 did transmit from animals to humans, further sampling in Hubei Province may identify more closely related SARSr-CoVs in archived animal specimens. Investigating the possibility of an infected person travelling to Wuhan and unwittingly spreading the virus will be more difficult in the absence of archived samples and records of travel history.

Despite the abundance of SARSr-CoVs and beta-CoVs in bat species [52, 53] , it is likely that additional reservoirs and intermediate hosts remain undetected [54] . Pigs, alpacas, and dromedary camels also maintain a variety of CoVs with the potential to transmit to humans [3, 12, 20, [55] [56] [57] . Independent insertions within RBDs of SARS-CoV, MERS-CoV, and SARS-CoV-2 suggest convergent evolution, which will likely lead to emergence of more pathogenic HCoVs [58] . Further sampling of bats, pangolins, and other species that share an ecological niche with bats may help piece together the puzzle surrounding the spill over of [20, [308] [309] [310] SARS-CoV-2 into humans [59] and also help discover other CoVs with potential to infect humans. Aside from consistent spill over of MERS-CoV from camels [60] , HCoVs have emerged through limited spill over events, followed by human-to-human transmission [3, 61] . While challenging to predict, future spill over events are likely, due to the long history of CoV host shifting [62] [63] [64] [65] . Anthropogenic factors such as urbanization and deforestation increase habitat overlap of humans and animals, providing increased zoonotic transmission opportunities [57, 66] . Areas of high contact between humans, wildlife, and domesticated animals, such as live animal wet markets provide opportunity for viral recombination and adaptation to a broader range of animal species prior to transmission to humans [57] . Identifying existing CoV diversity in such areas will enhance our understanding of ecological opportunities for zoonosis and will help us better predict and prevent the emergence of future HCoVs.

Co-evolution of CoVs with their hosts is driven by genetic diversity that is selected through evolutionary pressures. CoV genetic diversity is made possible by a large genome (26.4-31.7 kb) [67] , high mutation rate due to a low fidelity viral polymerase (~ 10 -4 substitutions per site per year) [68, 69] , and high recombination frequency (up to 25% for the entire genome in vivo) [70, 71] . Mutations that confer greater fitness are selected for, leading to antigenic drift. Ratios of the rates of non-synonymous/synonymous mutations (dN/dS) greater than one, less than one and equal to one indicate positive selection, negative (purifying) selection and neutral evolution, respectively [72] . SARS-CoV-2 genomes are currently under purifying selection [73, 74] . Despite observing little viral diversity at the beginning of the COVID-19 pandemic [75, 76] , positive selection with presumed advantages such as increased transmission rates has now been documented [77] [78] [79] (Fig. 2 , Table 2 ). However, functional characterization of these mutations remains under-investigated.

Antigenic drift is most frequently observed in viral surface proteins that are highly exposed to selection pressures of the immune system, such as neutralizing antibodies [80] . Indeed, CoV spike genes, particularly the S1 and RBD coding regions, have the highest detected non-synonymous mutation rates [81, 82] , a trend observed across the majority of HCoVs (Fig. 2) . For low pathogenic and endemic HCoVs, multiple positively selected for residues and polymorphic sites are found in the N-terminal domain (NTD) of S [83] [84] [85] [86] [87] [88] . A notable exception is HCoV-HKU1, for which there is a shortage of sequencing data outside of the hemagglutinin esterase (HE) gene. Emerging data suggest that positively selected for and homoplastic sites have been observed within the SARS-CoV-2 NTD as well [78, [89] [90] [91] . Given the observations with other HCoVs (Fig. 2 ) and the detection of neutralizing epitopes within the SARS-CoV-2 NTD [91, 92] , we speculate that with continued circulation, vaccination and convalescent sera therapy, further positively selected for mutations in the NTD are likely to occur. Further retrospective research on the evolution of endemic HCoVs may help predict the likely evolutionary trajectory of SARS-CoV-2.

CoV genomic mutations give rise to virus variants, and closely related variants are grouped into clades. SARS-CoV-2 variants have been clustered into nine clades: L, V, S, G, GH, GR, GV, GRY and O [93, 94] (Table 3) , named after their most representative mutations [95] . Clade L dominated the beginning of the pandemic [38], prior to the appearances of clade S and the less defined clade O in early January, 2020 [73, 93, 96] . Clades V and G appeared in mid-January, followed by clades GH and GR at the end of February, clade GV at the end of June, and clade GRY in September, 2020 [94, 97, 98] . Clades L and V are likely extinct, while clades G, GH, GR, and GRY comprise the majority of global SARS-CoV-2 sequences currently [97, 98] . Clade S has also been declining since the emergence of clade G [93] . Following rapid dissemination of clade G and its derivatives, such as B.1.1.7, B.1.351, P.1, and B.1.617.2 variants (Table 5) , we may see the rise of other variants, selected by mounting population-level immunity and other yet unidentified factors [89, [99] [100] [101] , highlighting the need for international genome surveillance efforts and global data sharing via the established GISAID resource [102] .

Clade G is characterized in part by the single nucleotide polymorphism (SNP) A23403G within subdomain 2 of the S1 gene, resulting in amino acid mutation D614G [103, 104] (Fig. 2 , Table 2 ). D614G is now detected globally in B.1.1.7, B,1,351, P.1, B.1.617.2 and other variants [97, 104, 105] and increases the infectivity of SARS-CoV-2 by increasing respiratory viral load [106, 107] , possibly due to increased S openness [108, 109] or cleavability [110] , causing this mutation to become dominant upon emergence [93, 111, 112] . There is also an epidemiological correlation between D614G and anosmia (loss of smell) [109] , potentially due to greater viral loads in the olfactory epithelium. Preliminary evidence suggests that D614G increases viral susceptibility to neutralization [113] , with uncertain impacts on disease severity [104, 114, 115] .

D614G is usually accompanied by three other mutations which represent clade G [104, 116, 117] (Table 3) . Of these mutations, P323L in the RNA-dependent RNA polymerase (RdRp), encoded by Nsp12 (Fig. 2 , Table 2 ), is particularly interesting as CoV RdRp tends to be highly Mutations identified in human coronaviruses. Red dots within the genomes correspond to specific amino acid residues that have been strongly positively selected for such that a specific mutation has become dominant in the region where it emerged [74, 78, 83-91, 94-96, 99-101, 104, 111, 116, 117, 121, 123-125, 129, 131, 132, 135, 138-140, 146, 151-154, 158, 162, 278, 284-293] . Genomic regions highlighted by red bars correspond to deletions that have been selected for, while purple bars correspond to regions with significant polymorphisms within a CoV species. Beta-CoV Lineage B (Sarbecovirus) is represented within the blue shaded area, beta-CoV Lineage C (Merbecovirus) is represented within the yellow shaded area, beta-CoV Lineage A (Embecovirus) is represented within the red shaded area, and alpha-CoVs are represented within the green shaded area. Genome length in kilobases (kb) is noted on top. See Table 2 for more details conserved by purifying selection given its critical role in viral genome replication [118, 119] (Table 4 ). P323 falls outside of the RdRp catalytic site and within a relatively uncharacterized interface domain that may interact with proteins that regulate viral polymerase function [120] . The correlation of this mutation with increased point mutations [121] elsewhere in the genome raises an intriguing hypothesis that P323L diminishes RdRp proofreading ability, leading to increased mutation rates. Moreover, P323L downregulates the association of Nsp12 with the Nsp8 primase subunit (Table 4) , reducing polymerase activity and viral replication [122] . Decreased replication could decrease symptomology, leading to reduced COVID-19 detection and greater population-level spread. It is important to characterize the cumulative effect of all mutations, as any reduction in transmission due to P323L could be compensated for by the co-existing D614G mutation. Multiple factors may contribute to the success of clade G and its derivatives via rapid spread with low detection in human populations [104] .

Positively selected for residues within SARS-CoV-2 Nsp6 [74, [123] [124] [125] [126] are intriguing since Nsp6 is relatively conserved in other coronaviruses [126] (Fig. 2 , Table 2 ). SARS-CoV-2 Nsp6 inhibits IFN-1 responses [127] and may reduce delivery of viral factors to host lysosomes similar to its SARS-CoV ortholog [128] ( Table 4 ). The Nsp6 L37F mutation may impair Nsp6 function [129] , decreasing viral replication and causing increased asymptomatic infections [130] . A similar homoplasy occurs in MERS-CoV Nsp6 [74, 131] (Fig. 2) , although the outcome of this mutation is unknown. The associated clade V mutation (Table 3) in ORF3a (G251V) reduces viral replication through decreased SARS-CoV-2 intraviral ORF3a-S and ORF3a-membrane protein (M) binding affinity [132] . Nsp6 (L37F) and ORF3a (G251V) mutations were likely selected to decrease pathogenicity and disease severity. A separate positively selected ORF3a mutation (Q57H) [111] characteristic of clade GH variants (Table 3) is speculated to increase ORF3a-S and ORF3a-M binding affinity, promoting virus replication [132] . The ORF3a viroporin is essential for SARS-CoV-2 pathogenesis [133] and limits apoptosis in infected cells relative to its SARS-CoV ortholog [134] , potentially contributing to less severe disease outcomes.

Another mutation of interest (L84S) lies within ORF8 [123, 124, 135] , a protein implicated in evasion of host immune responses [136, 137] (Table 4 ). ORF8 was under strong directional selection at the beginning of both SARS-CoV-2 [124] and SARS-CoV outbreaks [138] , supporting the theory that it facilitates zoonotic transmission and adaptation in alternate hosts [139, 140] . However, the over-representation of ORF8 deletions in SARS-CoV with no apparent effect on viral survival [138] suggests that ORF8 may be dispensable in humans [139] , and L84S mutations may not be significant. While This table illustrates positively selected for residues across multiple human coronaviruses. Shaded boxes represent proteins not encoded by the specific CoV species. Text in bold highlight mutations and deletions that were positively selected for and showed population-level expansion, while non-bolded text represents highly polymorphic sites. Sites are indicated as nucleotide (nt) position or amino acid (aa) position. Empty cells in the table represent lack of evidence for positive selection or lack of publications on positive selection within these regions S Spike glycoprotein Cleaved into S1 and S2 subunits. S1 binds host receptor (ACE2) while S2 mediates viral and host membrane fusion [333] ORF3a Orf3a viroporin Activates NF-kB and NLRP3 inflammasome to contribute to cytokine storm. Promotes viral release and may induce necrotic cell death [334] [335] [336] ORF3b Accessory protein ORF3b IFN-1 antagonist [337] E Envelope protein A viroporin involved in viral assembly, budding, and pathogenesis. Forms CoV envelope [338, 339] M Membrane protein Forms viral membrane and induces N and S localization to the ER-Golgi-Intermediate compartment for virion assembly and budding [340] ORF6 Accessory protein ORF6 IFN-1 antagonist [144] ORF7a Accessory protein ORF7a SARS-CoV ortholog inhibits bone marrow stromal antigen 2 mediated tethering of virions to host plasma membrane [341] ORF7b Accessory protein ORF7b SARS-CoV ortholog attenuates viral replication [342] ORF8 Accessory protein ORF8 Inhibits IFN-1 activity and downregulates MHC-1 expression to evade host immunity [136, 137, 144] N Nucleocapsid Involved in immune evasion through IFN-1 antagonism, nucleocapsid formation, viral RNA replication, and virion assembly [144, 145] ORF9b Accessory protein ORF9b Suppresses IFN-1 responses through inhibition of TOM70 [343] ORF9c Accessory protein ORF9c Interferes with IFN signalling, antigen presentation, and complement signalling. Induces IL-6 signalling [344] ORF10 Accessory protein ORF10 Interacts with a Cullin 2 RING E3 ligase complex to potentially modulate ubiquitination [345] clade GR [123] . RG203KR alters N protein morphology, resulting in increased intraviral protein binding affinity [132] . N-M interactions are necessary for CoV viral assembly [141, 142] , while N-envelope (E) interactions potentially increase production of virus-like particles [143] . Therefore, increased intraviral N protein binding affinities could contribute to increased viral replication. RG203KR may also confer immune evasion properties to SARS-CoV-2 considering the rapid expansion of clade GR and the role of N protein in antagonizing human antiviral immune responses [144, 145] ( Table 4 ). The global prevalence of variant B.1.1.7 has generated clade GRY from clade GR [146] . Clade GV is associated with the European variant 20A. EU1 containing spike NTD mutation A222V [105, 147] . A222 is located within a speculated B lymphocyte epitope [148] that may impact neutralization by human antibodies, consistent with observed SARS-CoV-2 re-infection with a clade GV variant [149] . The rise in prevalence of variant 20A.EU1 and clade GV is most likely associated with the relaxing of travel-associated restrictions across Europe near the end of the summer of 2020 considering the rapid decline in prevalence of global clade GV sequences in 2021 [97, 150] .

An aforementioned trend across HCoVs is positively selected residues within RBD [84, 85, 88, 138, 139, [151] [152] [153] [154] (Fig. 2, Table 2 ), which facilitates interactions with host cellular proteins, providing a crucial target for the host immune response [155] . Accordingly, SARS-CoV-2 RBD is rapidly evolving, leading to novel variants [156, 157] (Fig. 2, Table 2 ). SARS-CoV-2 variants associated with greater transmissibility, altered virulence, or the ability to escape natural infection-and vaccine-mediated immunity or current diagnostic tests are called Variants of Concern (VOC; Table 5 ).

Early data suggest that RBD mutation N501Y emerged recurrently in multiple regions due to increased transmissibility, and is associated with multiple VOCs [89, 99, 100, 158] (Table 5 ). SARS-CoV-2 N501 serves as one of six critical S residues required for binding to ACE2 [159] and N501Y increases viral infectivity through greater S-hACE2 binding affinity, likely due to stronger interactions with ACE2 residues Y41 and K353 [160] . Other critical residues within the SARS-CoV-2 RBD (L455, F486, Q493, S494, Y505) [73] should be closely monitored as mutations may increase SARS-CoV-2 transmission in humans and facilitate zooanthroponotic transfer to other species.

Early studies of the highly transmissible B.1.1.7 variant [77, 161] originating in the United Kingdom described 17 co-occurring non-synonymous mutations or deletions [89] , which are more than expected since the mutation rate of SARS-CoV-2 is estimated to be around 2.4 × 10 -3 per site per year [135] . In addition to N501Y, spike 69-70del, Y144del, and P681H mutations are speculated to be of functional significance [78, 162] (Table 5) . Spike NTD 69-70del variants have shown significant Table 5 SARS-CoV-2 variants of concern (as of July 22, 2021) Variant names are based on Rambaut et al.'s classification [347] . Other commonly used names are mentioned in brackets. Mutations mentioned here are nonsynonymous mutations that are speculated to confer some functional significance. These variants contain other mutations that may also contribute to viral advantages [89, [99] [100] [101] . Updated information about SARS-CoV-2 VOCs can be accessed through the GISAID resource (https:// www. gisaid. org). Dates of emergence are based on retrospective analyses. S, spike. del, deletion [196, 201, 202, 346] transmission expansion, with speculated increased resistance to antibody-mediated neutralization [92] likely associated with sequestration of a protruding spike loop [78] . Y144del confers antibody resistance due to loss of a negative surface charge [163, 164] . Spike P681 is located in a known CoV mutational hotspot [83, 101] directly adjacent to the SARS-CoV-2 S1/S2 furin cleavage site (aa 681-684) [89, 165, 166] which promotes virus entry into host cells [167] ; mutation in this region may increase cleavability and membrane fusion to enhance infectivity. P681 is also within an antigenic epitope recognized by B and T lymphocytes, implicating host immune response alterations [168] . P681H may therefore represent adaptive evolution to evade host immunity, although confirmatory studies are required. Another speculated B.1.1.7 mutation at ORF8 (Q27stop) causes early protein termination [89] . Truncated ORF8 has been associated with milder symptoms [169] , although increased mortality is also associated with the B.1.1.7 variant [79, 170] . Emerging mutations in B.1.1.7 must be monitored and investigated, such as the sub-lineage VOC202102/02 that contains the RBD mutation E484K, which is associated with antibody resistance [171] [172] [173] .

Another variant containing N501Y is B.1.351, which was first detected in South Africa in December, 2020 [100] , but likely originated in October, 2020 [101] . This variant contains eight non-synonymous mutations in S, including three within the RBD (K417N, E484K, N501Y) and three in the NTD that may contribute to increased transmissibility [100, 101] . Both N501Y and E484K are located within the receptor binding motif (RBM) of the RBD. E484 interacts with residue K31 on hACE2 [174] , one of two critical hACE2 RBD-interacting residues [159, 175] , suggesting that E484K may affect the binding affinity of SARS-CoV-2 with hACE2. However, preliminary studies demonstrate contradictory binding affinity observations [176, 177] ; further studies are required. In addition, E484K confers some resistance to antibodymediated neutralization of SARS-CoV-2 in vitro [91, 154, [178] [179] [180] [181] , consistent with the observation that E484 is an important recognition site for neutralizing antibodies [181, 182] , and raising concerns about E484K being an immune escape mutation appearing in multiple independent SARS-CoV-2 lineages [172, [183] [184] [185] [186] . Similarly, spike K417 is within a neutralizing antibody epitope [100] . Preliminary evidence suggests K417N reduces recognition by human antibodies [187] . K417N may impact RBD-hACE2 binding affinity and stabilize E484K, though these effects remain uncertain [91, 177, 187, 188] .

Mutations within the RBD (K417T, E484K, N501Y) have also been observed in the P.1 variant ( Table 5 ) that likely originated in Brazil and has since spread to other countries [101, [189] [190] [191] . In contrast, the P.2 variant only contains E484K, likely acquired through convergent evolution with P.1 [186, 192] . Little is known about the P.1 variant, but based on emerging data [193] , we speculate that the RBD mutations likely affect antibody-mediated neutralization and contribute to increased transmission as observed with B.1.351. Mutations shared between the B.1.1.7, B.1.351, and P.1 variants are speculated to have arisen independently, indicating convergent evolution [194] (Table 5 ). These variants also share Nsp6 3675-3677del, with unknown functional significance [194, 195] . VOC B.1.617.2 was first identified in India in late 2020 and contains positively selected for mutations within the spike protein, namely, L452R, T478K, and P681R, along with the D614G mutation [196] ( Table 5 ). Mutation of the uncharged and hydrophobic leucine (L) residue into the positively charged and hydrophilic arginine (R) residue at spike position 452 allows for an increased electrostatic interaction with negatively charged ACE2 residues E35, E37, and D38, likely leading to the observed increase in S-hACE2 complex stability, viral infectivity, and virus replication [196, 197] . Furthermore, abolition of the hydrophobic surface patch through the L452R mutation led to reduced antibody-mediated neutralization and cellular immune recognition [196] [197] [198] . Spike mutation T478K has also been shown to increase electrostatic interactions in the S-hACE2 complex and may increase binding affinity similar to the S477N mutation [199] . The mutation T478K is within a neutralizing epitope close to the immune evasion mutation E484K/Q that is present in multiple SARS-CoV-2 variants, including the ancestral B.1.617 lineage and current sub-lineages B.1.617.1 and B.1.617.2 [181, 200, 201] . T478K in combination with L452R may contribute to increased resistance to neutralization by monoclonal antibodies, convalescent sera, and vaccinated sera [201, 202] . B.1.617.2 has increased replication efficiency in human airway systems relative to the B.1.1.7 lineage due to enhanced spike cleavability, which is likely augmented by the P681R mutation [201, 203] . P681R is known to increase cell-to-cell fusion in the respiratory tract, potentially increasing transmissibility and pathogenicity in infected individuals [201, 203] . B.1.617.2 may thus represent a VOC with similar resistance to antibody neutralization as B.1.351 and transmissibility beyond B.1.1.7 [200] . Recently discovered B.1.617.2 sequences containing the K417N mutation (AY.1/AY.2 lineages) must be monitored for altered antibody resistance and increased transmissibility [204] .

Circulating variants containing an N439K mutation (e.g. B.1.141 and B.1.258) also show some degree of neutralization evasion [91, 198, 205] , raising speculations about SARS-CoV-2 variants escaping vaccine-mediated immunity. Emerging data suggest that antibodies elicited by mRNA vaccines (BNT162b2 and mRNA-1273) have 20% and 16.7% reduced neutralization capacity, respectively, against the B.1.1.7 variant [206, 207] and 67% and 84% reduced neutralization capacity, respectively, against the B.1.351 variant [208, 209] . Neutralization capacity of sera from BNT162b2 and mRNA-1273 vaccinated individuals have 87% and 52% reduced neutralization capacity, respectively, against the B.1.617.2 variant [200, 201, 210] . The emergence of B.1.1.7 sub-lineages containing the E484K RBD mutation (e.g. VOC202102/02) pose additional challenges for vaccine-mediated immunity [171, 173, 183] . While complete vaccine failure is unlikely [206, 207, [211] [212] [213] [214] [215] , immune escape variants may create a need to update current SARS-CoV-2 vaccines. Monitoring the emergence of novel SARS-CoV-2 variants is especially important as vaccine-mediated immunity provides stronger selective pressure for SARS-CoV-2 evolution.

Multiple emerging SARS-CoV-2 lineages are not considered VOCs but are still of interest and may become VOCs in the future. One variant, B.1.525, was first detected in December, 2020, in the United Kingdom and Nigeria and has since spread internationally. B.1.525 contains spike mutations 69-70del, E484K, Q677H, and F888L. Q677P/H has emerged in disparate variants and may affect spike cleavability similar to P681H [158, [216] [217] [218] . F888L lies between the fusion peptide and heptad repeat region of the S2 subunit [219] and may impact host cellular entry, similar to the impact of heptad repeat mutations in MERS-CoV [139, 220] .

Variant B.1.526 from New York contains spike mutations D253G, D614G, and A701V, along with either E484K or S477N, creating two major B.1.526 sub-lineages. NTD mutation D253G reduces antibody-mediated neutralization [163] . A701V, shared by variant B.1.351 [100] , is in the S2 subunit adjacent to the furin cleavage site [219] and may impact SARS-CoV-2 cleavability and infectivity. S477N, also found in variant 20A.EU2, increases binding to hACE2 [221, 222] and reduces antibody-mediated neutralization [178, 223] , likely due to its position within a neutralizing epitope [224] . D614G and E484K are shared with multiple other variants (Table 5) and likely play a role in B. [183, 225] . The UK A.23.1 sub-lineage VUI-202102/01 also contains immune escape mutation E484K [171, 183] . Preliminary data show increased ACE2 binding affinity and reduced antibody-mediated neutralization for the P.3 variant from Brazil, which contains the spike mutations E484K, N501Y, and P681H [164] . Data also suggest increased ACE2 binding affinity and reduced neutralization profile for the B.1.620 variant from Central Africa, which contains spike mutations E484K, S477N, D614G, and P681H [226] . Other notable variants include N440K variants from India [227] that have increased transmissibility, and the R.1 variant from Japan which contains potential immune escape mutations W152L and E484K [228] . [97, 230] . B.1.427/B.1.429 contains multiple positively selected for mutations within the S protein, such as S13I, W152C, and L452R, all of which contribute to some degree of resistance to antibody-mediated neutralization [229] . L452R has convergently evolved in the B.1.617 lineage and contributed to enhanced SARS-CoV-2 infectivity [196] [197] [198] (Table 5 ). Spike mutation L452Q was detected in the recently emerged C.37 lineage from Peru and is expected to have similar impacts on virus infectivity as the L452R mutation [231] . C.37 also shares Nsp6 3675-3677del with B.1.1.7, B.1.351. and P.1 variants [231] , and contains the spike RBD mutation F490S that has been associated with reduced antibody-mediated neutralization [91, 178] . These variants need to be monitored for transmission expansion and convergent evolution.

The future of SARS-CoV-2 and COVID-19 remains uncertain. Many virological, immunological, and social factors will influence the epidemiological trajectory of this virus. One particularly intriguing question that remains unanswered is whether SARS-CoV-2 will become endemic in the human population, like HCoVs NL63, OC43, HKU1, and 229E [232] [233] [234] .

Currently, endemic HCoVs cause seasonal outbreaks [235] , with increased circulation observed in the winter in temperate regions [232] . Cold temperatures are favourable for enveloped viruses [236] , as lower temperatures enhance lipid ordering of the viral envelope, allowing the virus to remain protected outside the host for longer periods of time [237, 238] . Low temperatures also enhance aerosol transmission of respiratory viruses by allowing virions to remain suspended in the air for a longer duration [239] . Furthermore, cold and dry environments can have immunosuppressive effects on a potential host, further increasing the chances of infection [240] [241] [242] . Evidence suggests decreased transmission of SARS-CoV-2 in warmer climates [243] [244] [245] [246] , likely due to degeneration of viral structural stability with increasing temperatures [247] . Decreased transmission of SARS-CoV-2 was not observed during the summer of 2020 [11, 248] likely because of the sheer number of cases and an immunologically naïve population. For seasonality to have an observable impact on SARS-CoV-2 transmission, the basic reproduction number (R 0 ) must drop from its current estimate of around 2.5 to less than 1 [249] . In theory, SARS-CoV-2 R 0 should drop substantially when population herd immunity is reached through natural infection and vaccination, allowing for meteorological factors to influence viral transmission, leading to seasonal fluctuations. Other intervention mechanisms such as effective social distancing, quarantine, and contact-tracing will contribute towards reducing the R 0 for SARS-CoV-2 [250, 251] .

Multiple studies have demonstrated short-lasting immunity to endemic HCoVs, with waning of protective immunity and re-infections common within 80 days [85] to one year [252] [253] [254] [255] . There is no observable association between endemic HCoV re-infection and infection severity [254] . Waning of humoral immunity within a year [256] [257] [258] [259] [260] and re-infection of immunocompetent patients [149] have been demonstrated for SARS-CoV-2, suggesting the possibility of annual outbreaks [233, 261] . A weaker initial immune response and sharper decline of antibody levels have been reported in individuals with asymptomatic SARS-CoV-2 infections [257, 258] . Thus, multiple exposures to SARS-CoV-2 may be required to develop sufficient immunity to prevent future re-infections, which may also be influenced by adaptive evolution of SARS-CoV-2 in the human population ( Table 5 ). The duration of protection through vaccination and natural exposures is being closely monitored, along with antigenic evolution of SARS-CoV-2 that may lead to immune escape. Indeed, the evolutionary trajectories of endemic HCoVs suggest that SARS-CoV-2 will evolve to co-exist with the human population. However, with roll-out of the first ever HCoV vaccines, predicting the evolutionary trajectory of SARS-CoV-2 remains challenging.

An important factor that may influence ongoing SARS-CoV-2 transmission is the potential for cross-protection by humoral and cellular immune responses induced by related endemic HCoVs. There is evidence of cross-protection within the same genera of HCoVs [233, 262, 263] , but not between genera [264] . Thus, immunity against beta-CoVs HCoV-OC43 and HCoV-HKU1 may provide some protection against COVID-19 [265] [266] [267] [268] , while immunity against alpha-CoVs HCoV-229E and HCoV-NL63 will likely provide little to no protection. Antibody-dependent enhancement has not been observed for SARS-CoV-2 [269, 270] , ruling out the possibility of increased disease severity by cross-reactive antibodies generated against endemic HCoVs. The high frequency of CoV recombination during co-infections raises the additional concern that SARS-CoV-2 recombination with seasonal HCoVs could generate novel CoVs [131, 271, 272] . The role of HCoV co-infection has not been reported or extensively studied and will be especially important for immunocompromised and elderly individuals.

SARS-CoV-2 continues to evolve and adapt to the human population as highlighted by the emergence of novel variants. Mutations within the spike protein of SARS-CoV-2 variants confer increased transmissibility and some degree of resistance to antibody-mediated neutralization. However, recurrent attenuating mutations, such as P323L, L37F, G251V, and Q27stop have also been identified and are speculated to reduce disease severity. The appearance of attenuating mutations suggests that SARS-CoV-2 is evolving to become less pathogenic in humans. The current SARS-CoV-2 pandemic is driven by asymptomatic, pre-symptomatic, or otherwise unrecognized cases [273] [274] [275] . Reduced pathogenicity of SARS-CoV-2 combined with mounting population-level immunity will likely cause a reduction of severe cases of COVID-19, leading to an apparent abatement of the pandemic, followed by endemic circulation of low pathogenic SARS-CoV-2 variants. A similar evolutionary trajectory may have led to the establishment of current low-pathogenic endemic HCoVs [276] .

Monitoring future emerging variants of SARS-CoV-2 is critical to determine control measures for the COVID-19 pandemic. Mutations speculated to reduce immune recognition, such as within the spike protein (S13I, 69-70del, W152L, A222V, K417N, N439K, S477N, T478K, E484K/Q, F490S, P681H/R) and nucleoprotein (RG203KR) should be studied for reduced sensitivity to natural or vaccine-induced immunity. Other factors, such as zoonotic and zooanthroponotic transmission of SARS-CoV-2, cross-protection through immunity against endemic HCoVs, and the possible creation of novel animal reservoirs through zooanthroponosis should continue to be investigated as they may have significant implications on the evolutionary trajectory of SARS-CoV-2 and the COVID-19 pandemic. travel-related cases, and vaccine readiness. J Infect Dev Ctries. 2020;14 (1) 

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus

Origin and evolution of pathogenic coronaviruses

Evolution, antigenicity and pathogenicity of global porcine epidemic diarrhea virus strains

Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin

Fenner's veterinary virology

Overview of lethal human coronaviruses

Human coronaviruses: what do they cause? Antivir Ther (Lond)

Middle East respiratory syndrome

COVID-19 Dashboard by the

Human coronaviruses: a review of virus-host interactions

COVID-19: molecular diagnostics overview

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

European Centre for Disease Prevention and Control. MERS-CoV worldwide overview. ECDC

The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts

High prevalence of MERS-CoV infection in camel workers in Saudi Arabia

Bat origin of a new human coronavirus: there and back again

Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation

Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history

Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats

Evolutionary insights into the ecology of coronaviruses

Infection, replication, and transmission of middle east respiratory syndrome coronavirus in alpacas

Replication and shedding of MERS-CoV in Jamaican fruit bats (Artibeus jamaicensis)

Middle east respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir

Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia

MERS-CoV in camels but not camel handlers

Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan

Predicting wildlife hosts of betacoronaviruses for SARS-CoV-2 sampling prioritization

Link of a ubiquitous human coronavirus to dromedary camels

Identification and characterization of a novel alpaca respiratory coronavirus most closely related to the human coronavirus 229E

Exploring human-animal host interactions and emergence of COVID-19: evolutionary and ecological dynamics

Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses

Unraveling the zoonotic origin and transmission of SARS-CoV-2

Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia

Hosts and sources of endemic human coronaviruses

SARS associated coronavirus has a recombinant polymerase and coronaviruses have a history of host-shifting

SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission

Molecular characterization of a canine respiratory coronavirus strain detected in Italy

Bovine-like coronaviruses isolated from four species of captive wild ruminants are homologous to bovine coronaviruses, based on complete genomic sequences

Interspecies transmission and emergence of novel viruses: lessons from bats and birds

Coronavirus genomics and bioinformatics analysis

Genetic variability of human respiratory coronavirus OC43

Genetic evolution and tropism of transmissible gastroenteritis coronaviruses

Establishing a genetic recombination map for murine coronavirus strain A59 complementation groups

Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus

The population genetics of dN/dS

On the origin and continuing evolution of SARS-CoV-2

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

Rampant C→U hypermutation in the genomes of SARS-CoV-2 and other coronaviruses: causes and consequences for their short-and long-term evolutionary trajectories

Regaining perspective on SARS-CoV-2 molecular tracing and its implications. medRxiv

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70. bioRxiv

Estimated transmissibility and impact of SARS-CoV-2 lineage B117 in England

Predicting adaptive evolution

A palindromic RNA sequence as a common breakpoint contributor to copy-choice recombination in SARS-COV-2

Structural insights into coronavirus entry

Analysis of human coronavirus 229E spike and nucleoprotein genes demonstrates genetic drift between chronologically distinct strains

Genetic drift of human coronavirus OC43 spike gene during adaptive evolution

Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya

Genomic analysis of 16 Colorado human NL63 coronaviruses identifies a new genotype, high sequence diversity in the N-terminal domain of the spike gene and evidence of recombination

Mosaic structure of human coronavirus NL63, one thousand years of evolution

Discovery of a subgenotype of human coronavirus NL63 associated with severe lower respiratory tract infection in China

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. medRxiv

GISAID. hCoV-19 analysis update

Geographic and genomic distribution of SARS-CoV-2 mutations

A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic

Genomic variance of the 2019-nCoV coronavirus

Global phylogeny updated by NextStrain. GISAID

Evolving infection paradox of SARS-CoV-2: fitness costs virulence?

European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. ECDC

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Emerging SARS-CoV-2 variants. COVID-19

GISAID: global initiative on sharing all influenza data-from vision to reality

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

Genetic variants of SARS-CoV-2-what do they mean?

Spike mutation D614G alters SARS-CoV-2 fitness

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

The SARS-CoV-2 spike variant D614G favors an open conformational state

Chemosensory dysfunction in COVID-19: integration of genetic and epidemiological data points to D614G spike protein variant as a contributing factor

Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?

Contributory role of SARS-CoV-2 genomic variations and life expectancy in COVID-19 transmission and low fatality rate in Africa

Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant

D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. medRxiv

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate

A unique clade of SARS-CoV-2 viruses is associated with lower viral loads in patient upper airways

Genetic diversity of SARS-CoV-2 and clinical, epidemiological characteristics of COVID-19 patients in Hanoi

Variant analysis of SARS-CoV-2 genomes

A cell-based reporter assay for screening inhibitors of MERS coronavirus RNA-dependent RNA polymerase activity

RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Emerging SARS-CoV-2 mutation hot spots include a novel RNAdependent-RNA polymerase variant

Epidemiologically most successful SARS-CoV-2 variant: concurrent mutations in RNA-dependent RNA polymerase and spike protein

New pathways of mutational change in SARS-CoV-2 proteomes involve regions of intrinsic disorder important for virus replication and release

Positive selection of ORF1ab, ORF3a, and ORF8 genes drives the early evolutionary trends of SARS-CoV-2 during the 2020 COVID-19 pandemic

Patterns of within-host genetic diversity in SARS-CoV-2. bioRxiv

An exclusive 42 amino acid signature in pp1ab protein provides insights into the evolutive history of the 2019 novel human-pathogenic coronavirus (SARS-CoV-2)

Evasion of Type I Interferon by SARS-CoV-2

Coronavirus NSP6 restricts autophagosome expansion

Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy

Decoding asymptomatic COVID-19 infection and transmission

MERS-CoV recombination: implications about the reservoir and potential for adaptation

Effects of SARS-CoV-2 mutations on protein structures and intraviral protein-protein interactions

SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis

The ORF3a protein of SARS-CoV-2 induces apoptosis in cells

The origin and underlying driving forces of the SARS-CoV-2 outbreak

The ORF8 protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-I. bioRxiv

Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein

The Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China

Molecular evolution of human coronavirus genomes

Severe acute respiratory syndrome (SARS) coronavirus ORF8 Protein Is acquired from SARS-related coronavirus from greater horseshoe bats through recombination

Characterization of protein-protein interactions between the nucleocapsid protein and membrane protein of the SARS coronavirus

The molecular biology of coronaviruses

The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells

Clade and lineage nomenclature aids in genomic epidemiology studies of active hCoV-19 viruses. Clade and lineage nomenclature

The newly introduced SARS-CoV-2 variant A222V is rapidly spreading in Lazio region, Italy. medRxiv

Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients

Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing

Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. medRxiv

Receptor-binding loops in alphacoronavirus adaptation and evolution

Spread of mutant middle east respiratory syndrome coronavirus with reduced affinity to human CD26 during the South Korean Outbreak

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Complete mapping of mutations to the SARS-CoV-2 spike receptorbinding domain that escape antibody recognition

Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided highresolution serology

One year of SARS-CoV-2 evolution

Mutations strengthened SARS-CoV-2 infectivity

Distinct patterns of emergence of SARS-CoV-2 spike variants including N501Y in clinical samples in Columbus Ohio

Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus

The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation

SARS-CoV-2 variant under investigation 202012/01 has more than twofold replicative advantage

Detection of SARS-CoV-2 P681H spike protein variant in Nigeria

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Structural analysis of spike protein mutations in an emergent SARS-CoV-2 variant from the Philippines

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin

A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells

The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells

Identification of SARS-CoV-2 vaccine epitopes predicted to induce long-term population-scale immunity

Lost in deletion: the enigmatic ORF8 protein of SARS-CoV-2

NERVTAG paper on COVID-19 variant of concern B.1.1.7: paper from the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) on new coronavirus (COVID-19) variant B.1.1.7. New and Emerging Respiratory Virus Threats Advisory Group

PHE statement on variant of concern and new variant under investigation. Gov.UK; 2021

Covid-19: The E484K mutation and the risks it poses

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies

Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method

Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection

Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant

Impact of South African 501V2 variant on SARS-CoV-2 spike infectivity and neutralization: a structure-based computational assessment

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv

Evolution of antibody immunity to SARS-CoV-2

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Variants: distribution of cases data

E484K as an innovative phylogenetic event for viral evolution: genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil

SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study

In silico investigation of the new UK (B117) and South African (501YV2) SARS-CoV-2 variants with a focus at the ACE2-spike RBD interface

Brief report: new variant strain of SARS-CoV-2 identified in travelers from Brazil. National Institute of Infectious Diseases

European Centre for Disease Prevention and Control. Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA-first update. ECDC

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

Genomic evidence of a Sars-Cov-2 reinfection case with E484K spike mutation in Brazil

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings-SARS-CoV-2 coronavirus/ nCoV-2019 genomic epidemiology

Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin. Microbiology

SARS-CoV-2 variants of concern and variants under investigation in England

Circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant

Neutralization of SARS-CoV-2 lineage B117 pseudovirus by BNT162b2 vaccine-elicited human sera

Neutralizing activity of BNT162b2-elicited serum-preliminary report

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants

Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa. Moderna

Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein in cell culture

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Effectiveness of covid-19 vaccines against the B16172 (Delta) variant

Emergence in late 2020 of multiple lineages of SARS-CoV-2 spike protein variants affecting amino acid position 677

Genome-wide identification and characterization of point mutations in the SARS-CoV-2 genome

Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

The heptad repeat region is a major selection target in MERS-CoV and related coronaviruses

SARS-CoV-2 receptor binding mutations and antibody mediated immunity

Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2

SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants

Immunoinformatic analysis of T-and B-cell epitopes for SARS-CoV-2 vaccine design. Vaccines

A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic

Travel-driven emergence and spread of SARS-CoV-2 lineage B.1.620 with multiple VOC-like mutations and deletions in Europe

Harinivas Harshan K. N440K variant of SARS-CoV-2 has higher infectious fitness

Detection of R1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/ G769V mutations in Japan

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. Immunology

World Health Organization. Tracking SARS-CoV-2 variants. WHO

The emergence of SARS-CoV-2 variant lambda (C.37) in South America

Seasonality of respiratory viral infections: will COVID-19 follow suit? Front Public Health

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Will coronavirus disease 2019 become seasonal?

Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan

Association between viral seasonality and meteorological factors

Progressive ordering with decreasing temperature of the phospholipids of influenza virus

Humidity and respiratory virus transmission in tropical and temperate settings

Airborne micro-organisms: survival tests with four viruses

Cold exposure and immune function

An explanation for the seasonality of acute upper respiratory tract viral infections

Low ambient humidity impairs barrier function and innate resistance against influenza infection

Temperature and latitude analysis to predict potential spread and seasonality for COVID-19

Will coronavirus pandemic diminish by summer? Social Science Research Network

High temperature and high humidity reduce the transmission of COVID-19

Predicting the local COVID-19 outbreak around the world with meteorological conditions: a model-based qualitative study

Structural stability of SARS-CoV-2 virus like particles degrades with temperature

An interactive web-based dashboard to track COVID-19 in real time

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2

The role of environmental factors on transmission rates of the COVID-19 outbreak: an initial assessment in two spatial scales

Seasonal coronavirus protective immunity is short-lasting

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study

Direct observation of repeated infections with endemic coronaviruses

The time course of the immune response to experimental coronavirus infection of man

Humoral responses and serological assays in SARS-CoV-2 infections

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection

Will SARS-CoV-2 become endemic?

Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests

An outbreak of human coronavirus OC43 infection and serological cross-reactivity with SARS coronavirus

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Development of an inactivated vaccine candidate for SARS-CoV-2

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Predicting mammalian hosts in which novel coronaviruses can be generated

Extensive recombination-driven coronavirus diversification expands the pool of potential pandemic pathogens

Asymptomatic SARS coronavirus 2 infection: invisible yet invincible

Asymptomatic transmission, the achilles' heel of current strategies to control covid-19

Zoonotic origins of human coronaviruses

Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event

Human respiratory coronavirus OC43: genetic stability and neuroinvasion

Betacoronavirus adaptation to humans involved progressive loss of hemagglutinin-esterase lectin activity

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus

Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China

Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat

Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak

Evidence of severe acute respiratory syndrome coronavirus 2 reinfection after recovery from mild coronavirus disease 2019

Coronaviridae-old friends, new enemy! Oral Dis

SARS-CoV genome polymorphism: a bioinformatics study

Molecular evolution and structural mapping of N-terminal domain in spike gene of middle east respiratory syndrome coronavirus (MERS-CoV)

Spread, circulation, and evolution of the middle east respiratory syndrome coronavirus

Molecular evolution of MERS coronavirus: dromedaries as a recent intermediate host or long-time animal reservoir?

Extensive positive selection drives the evolution of nonstructural proteins in lineage c betacoronaviruses

Evolving sequence mutations in the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

EM structure of coronavirus-HKU1

haemagglutinin esterase reveals architectural changes arising from prolonged circulation in humans

Differences in neutralizing antigenicity between laboratory and clinical isolates of HCoV-229E isolated in Japan in 2004-2008 depend on the S1 region sequence of the spike protein

A novel coronavirus from patients with pneumonia in China

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

ORF8-related genetic evidence for Chinese horseshoe bats as the source of human severe acute respiratory syndrome coronavirus

Update: outbreak of severe acute respiratory syndrome-Worldwide

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Close relative of human middle east respiratory syndrome coronavirus in Bat

Middle east respiratory syndrome coronavirus in Bats, Saudi Arabia

Further evidence for bats as the evolutionary source of middle east respiratory syndrome coronavirus

Receptor usage of a novel bat lineage C betacoronavirus reveals evolution of middle east respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding

Human betacoronavirus 2c EMC/2012-related viruses in Bats, Ghana and Europe

Detection and full genome characterization of two beta CoV viruses related to Middle East respiratory syndrome from bats in Italy

Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease

A new virus isolated from the human respiratory tract

Evidence supporting a zoonotic origin of human coronavirus strain NL63

Identification of a new human coronavirus

A previously undescribed coronavirus associated with respiratory disease in humans

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

The large 386-nt deletion in SARS-associated coronavirus: evidence for quasispecies?

Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China

Crosshost evolution of severe acute respiratory syndrome coronavirus in palm civet and human

Reconstruction of the most recent common ancestor sequences of SARS-Cov S gene and detection of adaptive evolution in the spike protein

Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy*

Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization

Molecular evolution of human coronavirus 229E in Hong Kong and a fatal COVID-19 case involving coinfection with a novel human coronavirus 229E genogroup. mSphere

Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. GenBank

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Twoamino acids change in the nsp4 of SARS coronavirus abolishes viral replication

In silico proteome analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Biochemical screening for SARS-CoV-2 main protease inhibitors

The nonstructural proteins directing coronavirus RNA synthesis and processing

A high ATP concentration enhances the cooperative translocation of the SARS coronavirus helicase nsP13 in the unwinding of duplex

The curious case of the nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity

Overcoming nonstructural protein 15-nidoviral uridylate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2

Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Severe acute respiratory syndrome coronavirus ORF3a protein research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

SARS-CoV-2 viroporin triggers the NLRP3 inflammatory pathway

SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes

Loss of orf3b in the circulating SARS-CoV-2 strains

Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis

SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine

Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein

Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference

Reverse genetic characterization of the natural genomic deletion in SARS-Coronavirus strain Frankfurt-1 open reading frame 7b reveals an attenuating function of the 7b protein in-vitro and in-vivo

SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70

SARS-CoV-2 ORF9c is a membrane-associated protein that suppresses antiviral responses in cells

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

European Centre for Disease Prevention and Control. Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. ECDC

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

None.